clinical trial · NCT06969430
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Debiopharm International SA·phase2·recruiting·n = 134
Acute Myeloid LeukemiaDebio 1562M
brief summary
The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.
started
May 30, 2025
primary completion
Nov 1, 2031
completion
Nov 1, 2031
last updated
Mar 30, 2026
official title
A Phase 1/2, First-in-human, Multicenter, Open-label Trial Evaluating the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol